Virtual Evolution of HVEM Segment for Checkpoint Inhibitor Discovery
Immune therapy has emerged as an effective treatment against cancers. Inspired by the PD-1/PD-L1 antibodies, which have achieved great success in clinical, other immune checkpoint proteins have drawn increasing attention in cancer research. B and T lymphocyte attenuator (BTLA) and herpes virus entry...
Main Authors: | Mingjia Yu, Huimin Zhao, Yuhui Miao, Shi-Zhong Luo, Song Xue |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-06-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/22/12/6638 |
Similar Items
-
Blockade of HVEM for Prostate Cancer Immunotherapy in Humanized Mice
by: Nicolas Aubert, et al.
Published: (2021-06-01) -
Peptide and peptide-inspired checkpoint inhibitors: Protein fragments to cancer immunotherapy
by: Pottayil G. Sasikumar, et al.
Published: (2020-12-01) -
Not All Immune Checkpoints Are Created Equal
by: Annika De Sousa Linhares, et al.
Published: (2018-08-01) -
Combination checkpoint therapy with anti-PD-1 and anti-BTLA results in a synergistic therapeutic effect against murine glioblastoma
by: John Choi, et al.
Published: (2021-01-01) -
Immunothérapie du cancer par administration d’anticorps monoclonaux anti-HVEM ou anti-ICOS chez la souris humanisée : potentiel thérapeutique et effets immunologiques
by: Brunel, Simon
Published: (2017)